23rd Annual EuroMeeting of the Drug Information Association
- PDF / 125,032 Bytes
- 6 Pages / 612 x 794 pts Page_size
- 5 Downloads / 192 Views
MEETING REPORT
ª 2011 Adis Data Information BV. All rights reserved.
23rd Annual EuroMeeting of the Drug Information Association 28-30 March 2011; Geneva, Switzerland Mary Ellen Kitler Associates for Business and Research, Rolle, Switzerland
The Drug Information Association (DIA), which was founded in 1964, is a neutral, professional, non-profit organization whose members are active in the health sciences. The DIA is based in the US and has offices in Switzerland, Japan, India and China. DIA members are involved in the discovery, development, regulation, surveillance or marketing of pharmaceuticals, medical devices or related products. The DIA provides a global forum by organizing meetings and by organizing educational courses. This EuroMeeting had approximately 2100 attendees from 58 countries, including the EU, Argentina, Australia, Brazil, Gambia, India, Israel, Japan, Jordan, People’s Republic of China, Russian Federation, Serbia, Switzerland, Taiwan, Tanzania, United Arab Emirates and the US. The EuroMeeting comprised 17 pre-conference tutorials and 129 sessions within 16 themes. Themes included Securing Approvals in a Changing Environment, Developing Medicines for Special Populations, and Pharma e-World. The 426 speakers included representatives from the European Medicines Agency (EMA), the US FDA, the Pharmaceuticals and Medical Devices Agency, Japan (PMDA) and the Federal Institute for Drugs and Medical Devices, Germany (BfArM). The 180 exhibitors included potential suppliers, personnel recruitment companies, patient organizations and several regulatory agencies. 1. The Opening Plenary John Dalli, the European Commissioner responsible for Health and Consumer Policy, gave the keynote address. Mr Dalli discussed several issues that were important for health and consumer policy. The issues included overcoming health inequities, the need to keep health expenditures under control, ensuring access to all innovative medications, the monitoring of medicine safety and management of pharmacovigilance, the fight against counterfeit and poor-quality medications,
defending patient rights by having a uniform set of rules across the entire EU, and supporting the member states so they can continue to provide quality healthcare, to encourage innovation in pharmaceuticals, to strengthen medical device regulations and to ensure the development of personalized medicines to benefit patients. Dr Valdo Arnera, General Manager, PHT Corporation, Switzerland, and co-chairman of the EuroMeeting, explained that the pharmaceutical industry needs to rebuild public trust. Counterfeit and poor-quality medications are an increasing threat to public health. It is important to keep the public well informed about public health threats. It is not acceptable to keep patients ‘in the dark’, such as happened with the recent H1N1 flu epidemic. Dr June Raine, Director, Division of Vigilance Risk Management of Medicines, Medicines and Healthcare products Regulatory Agency (MHRA) and co-chairman of the EuroMeeting stated that one of the major cha
Data Loading...
